For the quarter ended December 2025, Chemours (CC) reported revenue of $1.33 billion, down 2.2% over the same period last year. EPS came in at $0.05, compared to $0.11 in the year-ago quarter.
The reported revenue represents no surprise over the Zacks Consensus Estimate of $1.33 billion. With the consensus EPS estimate being $0, the EPS surprise was +2400%.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Chemours performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenues- Other Segment: $12 million versus the four-analyst average estimate of $12.65 million. The reported number represents a year-over-year change of -7.7%.
- Revenues- Titanium Technologies: $561 million compared to the $548.65 million average estimate based on four analysts. The reported number represents a change of -11.2% year over year.
- Revenues- Advanced Performance Materials: $312 million versus $302.82 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -3.7% change.
- Revenues- Thermal & Specialized Solutions: $444 million versus $447.37 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +13.9% change.
- Adjusted EBITDA- Titanium Technologies: $23 million versus $17.47 million estimated by four analysts on average.
- Adjusted EBITDA- Other Segment: $1 million compared to the $0.87 million average estimate based on four analysts.
- Adjusted EBITDA- Advanced Performance Materials: $12 million versus $34.36 million estimated by four analysts on average.
- Adjusted EBITDA- Thermal & Specialized Solutions: $128 million compared to the $135.12 million average estimate based on four analysts.
View all Key Company Metrics for Chemours here>>>
Shares of Chemours have returned +30.6% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
The Chemours Company (CC): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
